<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">34055635</PMID>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2234-943X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in oncology</Title>
          <ISOAbbreviation>Front Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies.</ArticleTitle>
        <Pagination>
          <StartPage>668162</StartPage>
          <MedlinePgn>668162</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">668162</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fonc.2021.668162</ELocationID>
        <Abstract>
          <AbstractText>Bruton tyrosine kinase (BTK) is a validated target for treatment of B-cell malignancies, and oral inhibitors of BTK have emerged as a standard of care for these diseases. Acalabrutinib is a second generation, highly selective, potent, covalent BTK inhibitor that exhibits minimal off-target activity in <i>in vitro</i> assays, providing the potential to improve tolerability over the first-in-class BTK inhibitor, ibrutinib. Acalabrutinib was approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) in the US in 2017 and 2019, respectively. Acalabrutinib is also undergoing trials for other B-cell malignancies, both as monotherapy and in combinations. In this review, we discuss results from clinical trials evaluating the efficacy and safety of acalabrutinib in patients with CLL, MCL, and Waldenstrom's macroglobulinemia. Recent phase 3 data showed that acalabrutinib improved progression-free survival (PFS) compared with rituximab plus idelalisib or rituximab plus bendamustine in patients with relapsed/refractory CLL, and acalabrutinib with or without obinutuzumab improved PFS compared with chlorambucil plus obinutuzumab in patients with treatment-naïve CLL. Overall, acalabrutinib had a tolerable safety profile, with most adverse events being grade 1/2 severity (most commonly headache and diarrhea) and a low rate of discontinuation due to adverse events.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Abbas and Wierda.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Abbas</LastName>
            <ForeName>Hussein A</ForeName>
            <Initials>HA</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Cancer Medicine, Medical Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wierda</LastName>
            <ForeName>William G</ForeName>
            <Initials>WG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Oncol</MedlineTA>
        <NlmUniqueID>101568867</NlmUniqueID>
        <ISSNLinking>2234-943X</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">B-cell malignancies</Keyword>
        <Keyword MajorTopicYN="N">Bruton tyrosine kinase inhibitor</Keyword>
        <Keyword MajorTopicYN="N">Waldenstrom’s macroglobulinemia</Keyword>
        <Keyword MajorTopicYN="N">acalabrutinib</Keyword>
        <Keyword MajorTopicYN="N">chronic lymphocytic leukemia</Keyword>
        <Keyword MajorTopicYN="N">mantle cell lymphoma</Keyword>
      </KeywordList>
      <CoiStatement>WW has received research funding from AbbVie, Acerta Pharma, Emergent, Genentech, Gilead, GlaxoSmithKline/Novartis, Janssen, Juno, Karyopharm, Kite, and Pharmacyclics. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from Astra Zeneca LP. The funder had the following involvement in the study: medical writing support.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>17</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34055635</ArticleId>
        <ArticleId IdType="pmc">PMC8162209</ArticleId>
        <ArticleId IdType="doi">10.3389/fonc.2021.668162</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER) . Cancer Stat Facts: non-Hodgkin Lymphoma. Available at: https://seer.cancer.gov/statfacts/html/nhl.html (Accessed January 22, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>
Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin Lymphoma Subtype Distribution, Geodemographic Patterns, and Survival in the US: A Longitudinal Analysis of the National Cancer Data Base From 1998 to 2011. Am J Hematol (2015) 90:790–5.  10.1002/ajh.24086
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.24086</ArticleId>
            <ArticleId IdType="pubmed">26096944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vetrie D, Vořechovský I, Sideras P, Holland J, Davies A, Flinter F, et al. . The Gene Involved in X-linked Agammaglobulinaemia is a Member of the Src Family of Protein-Tyrosine Kinases. Nature (1993) 361:226–33.  10.1038/361226a0
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/361226a0</ArticleId>
            <ArticleId IdType="pubmed">8380905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al. . Deficient Expression of a B Cell Cytoplasmic Tyrosine Kinase in Human X-linked Agammaglobulinemia. Cell (1993) 72:279–90.  10.1016/0092-8674(93)90667-f
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0092-8674(93)90667-f</ArticleId>
            <ArticleId IdType="pubmed">8425221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gururajan M, Jennings CD, Bondada S. Cutting Edge: Constitutive B Cell Receptor Signaling is Critical for Basal Growth of B Lymphoma. J Immunol (2006) 176:5715–9.  10.4049/jimmunol.176.10.5715
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.176.10.5715</ArticleId>
            <ArticleId IdType="pubmed">16670274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
AstraZeneca . US FDA Approves Astrazeneca’s Calquence (Acalabrutinib) for Adult Patients With Previously-Treated Mantle Cell Lymphoma [Press Release] (2017). Available at: https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-approves-astrazenecas-calquence-acalabrutinib-for-adult-patients-with-previously-treated-mantle-cell-lymphoma-24102017.html# (Accessed January 22, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>
de Claro RA, McGinn KM, Verdun N, Lee SL, Chiu HJ, Saber H, et al. . FDA Approval: Ibrutinib for Patients With Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia. Clin Cancer Res (2015) 21:3586–90.  10.1158/1078-0432.CCR-14-2225
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-2225</ArticleId>
            <ArticleId IdType="pubmed">26275952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Janssen. Imbruvica (Ibrutinib) [Prescribing Information]. Sunnyvale, CA: Pharmacyclics LLC;  (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. . Targeting BTK With Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med (2013) 369:507–16.  10.1056/NEJMoa1306220
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1306220</ArticleId>
            <ArticleId IdType="pmc">PMC4513941</ArticleId>
            <ArticleId IdType="pubmed">23782157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. . Ibrutinib Regimens Versus Chemoimmunotherapy in Older Patients With Untreated CLL. N Engl J Med (2018) 379:2517–28.  10.1056/NEJMoa1812836
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1812836</ArticleId>
            <ArticleId IdType="pmc">PMC6325637</ArticleId>
            <ArticleId IdType="pubmed">30501481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shanafelt TD, Wang XV, Kay NE, Hanson CA, O’Brien S, Barrientos J, et al. . Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med (2019) 381:432–43.  10.1056/NEJMoa1817073
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1817073</ArticleId>
            <ArticleId IdType="pmc">PMC6908306</ArticleId>
            <ArticleId IdType="pubmed">31365801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, et al. . Long-Term Efficacy and Safety of First-Line Ibrutinib Treatment for Patients With CLL/SLL: 5 Years of Follow-Up From the Phase 3 RESONATE-2 Study. Leukemia (2020) 34:787–98.  10.1038/s41375-019-0602-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41375-019-0602-x</ArticleId>
            <ArticleId IdType="pmc">PMC7214263</ArticleId>
            <ArticleId IdType="pubmed">31628428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Caron F, Leong DP, Hillis C, Fraser G, Siegal D. Current Understanding of Bleeding With Ibrutinib Use: A Systematic Review and Meta-Analysis. Blood Adv (2017) 1:772–8.  10.1182/bloodadvances.2016001883
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/bloodadvances.2016001883</ArticleId>
            <ArticleId IdType="pmc">PMC5728050</ArticleId>
            <ArticleId IdType="pubmed">29296721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG, et al. . Ibrutinib-Associated Atrial Fibrillation. JACC Clin Electrophysiol (2018) 4:1491–500.  10.1016/j.jacep.2018.06.004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacep.2018.06.004</ArticleId>
            <ArticleId IdType="pubmed">30573111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Caldeira D, Alves D, Costa J, Ferreira JJ, Pinto FJ. Ibrutinib Increases the Risk of Hypertension and Atrial Fibrillation: Systematic Review and Meta-Analysis. PloS One (2019) 14:e0211228.  10.1371/journal.pone.0211228
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0211228</ArticleId>
            <ArticleId IdType="pmc">PMC6382095</ArticleId>
            <ArticleId IdType="pubmed">30785921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, et al. . Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor With a Differentiated Selectivity and In Vivo Potency Profile. J Pharmacol Exp Ther (2017) 363:240–52.  10.1124/jpet.117.242909
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/jpet.117.242909</ArticleId>
            <ArticleId IdType="pubmed">28882879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, et al. . BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol (2017) 35:1437–43.  10.1200/JCO.2016.70.2282
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.70.2282</ArticleId>
            <ArticleId IdType="pmc">PMC5455463</ArticleId>
            <ArticleId IdType="pubmed">28418267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. . Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib. N Engl J Med (2014) 370:2286–94.  10.1056/NEJMoa1400029
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1400029</ArticleId>
            <ArticleId IdType="pmc">PMC4144824</ArticleId>
            <ArticleId IdType="pubmed">24869598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
AstraZeneca . Calquence (Acalabrutinib) [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP;  (2019).</Citation>
        </Reference>
        <Reference>
          <Citation>
U.S. Food and Drug Administration . FDA Takes Second Action Under International Collaboration, Approves New Treatment Option for Patients With Chronic Lymphocytic Leukemia [FDA News Release] (2019). Available at: https://www.fda.gov/news-events/press-announcements/fda-takes-second-action-under-international-collaboration-approves-new-treatment-option-patients (Accessed January 22, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. . Acalabrutinib With or Without Obinutuzumab Versus Chlorambucil and Obinutuzmab for Treatment-Naive Chronic Lymphocytic Leukaemia (ELEVATE TN): A Randomised, Controlled, Phase 3 Trial. Lancet (2020) 395:1278–91.  10.1016/S0140-6736(20)30262-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30262-2</ArticleId>
            <ArticleId IdType="pmc">PMC8151619</ArticleId>
            <ArticleId IdType="pubmed">32305093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, et al. . Ascend: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol (2020) 38:2849–61.  10.1200/JCO.19.03355
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.19.03355</ArticleId>
            <ArticleId IdType="pubmed">32459600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. . Acalabrutinib in Relapsed or Refractory Mantle Cell Lymphoma (ACE-LY-004): A Single-Arm, Multicentre, Phase 2 Trial. Lancet (2018) 391:659–67.  10.1016/S0140-6736(17)33108-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(17)33108-2</ArticleId>
            <ArticleId IdType="pmc">PMC7864374</ArticleId>
            <ArticleId IdType="pubmed">29241979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. . Durable Response With Single-Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma. Leukemia (2019) 33:2762–6.  10.1038/s41375-019-0575-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41375-019-0575-9</ArticleId>
            <ArticleId IdType="pubmed">31558766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Owen RG, McCarthy H, Rule S, D’Sa S, Thomas SK, Tournilhac O, et al. . Acalabrutinib Monotherapy in Patients With Waldenstrom Macroglobulinemia: A Single-Arm, Multicentre, Phase 2 Study. Lancet Haematol (2020) 7:e112–e21.  10.1016/S2352-3026(19)30210-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2352-3026(19)30210-8</ArticleId>
            <ArticleId IdType="pubmed">31866281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Owen RG, McCarthy H, Rule S, D’Sa S, Thomas S, Foroni F, et al. . Acalabrutinib in Patients (Pts) With Waldenström Macroglobulinemia (WM) [Abstract]. J Clin Oncol (2018) 36(15 Suppl):Abstract 7501.  10.1200/JCO.2018.36.15_suppl.7501
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.36.15_suppl.7501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. . Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. N Engl J Med (2014) 371:213–23.  10.1056/NEJMoa1400376
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1400376</ArticleId>
            <ArticleId IdType="pmc">PMC4134521</ArticleId>
            <ArticleId IdType="pubmed">24881631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Munir T, Brown JR, O’Brien S, Barrientos JC, Barr PM, Reddy NM, et al. . Final Analysis From RESONATE: Up to Six Years of Follow-Up on Ibrutinib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Am J Hematol (2019) 94:1353–63.  10.1002/ajh.25638
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.25638</ArticleId>
            <ArticleId IdType="pmc">PMC6899718</ArticleId>
            <ArticleId IdType="pubmed">31512258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. . Ibrutinib in Previously Treated Waldenstrom’s Macroglobulinemia. N Engl J Med (2015) 372:1430–40.  10.1056/NEJMoa1501548
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1501548</ArticleId>
            <ArticleId IdType="pubmed">25853747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. . Ibrutinib as Initial Therapy for Patients With Chronic Lymphocytic Leukemia. N Engl J Med (2015) 373:2425–37.  10.1056/NEJMoa1509388
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1509388</ArticleId>
            <ArticleId IdType="pmc">PMC4722809</ArticleId>
            <ArticleId IdType="pubmed">26639149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li N, Sun Z, Liu Y, Guo M, Zhang Y, Zhou D, et al. . Bgb-3111 is a Novel and Highly Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor [Abstract]. Cancer Res (2015) 75(15 Suppl):Abstract 2597. 10.1158/1538-7445.AM2015-2597
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1538-7445.AM2015-2597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
U.S. Food and Drug Administration . FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma (2019). Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanubrutinib-mantle-cell-lymphoma (Accessed January 22, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>
Tam CS, LeBlond V, Novotny W, Owen RG, Tedeschi A, Atwal S, et al. . A Head-to-Head Phase III Study Comparing Zanubrutinib Versus Ibrutinib in Patients With Waldenstrom Macroglobulinemia. Future Oncol (2018) 14:2229–37.  10.2217/fon-2018-0163
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/fon-2018-0163</ArticleId>
            <ArticleId IdType="pubmed">29869556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cull G, Simpson D, Opat S, Burger JA, Trotman J, Marlton P, et al. . Treatment With the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results From a Phase 1/2 Trial [Abstract]. Blood
134(Suppl 1):500. 10.1182/blood-2019-125483
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2019-125483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, et al. . Phase 1 Study of the Selective BTK Inhibitor Zanubrutinib in B-cell Malignancies and Safety and Efficacy Evaluation in CLL. Blood (2019) 134:851–9.  10.1182/blood.2019001160
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.2019001160</ArticleId>
            <ArticleId IdType="pmc">PMC6742923</ArticleId>
            <ArticleId IdType="pubmed">31340982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tam CS, Opat S, D’Sa S, Jurczak W, Lee HP, Cull G, et al. . A Randomized Phase 3 Trial of Zanubrutinib vs Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: The ASPEN Study. Blood (2020) 136:2038–50.  10.1182/blood.2020006844
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.2020006844</ArticleId>
            <ArticleId IdType="pmc">PMC7596850</ArticleId>
            <ArticleId IdType="pubmed">32731259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee-Verges E, Hanna BS, Yazdanparast H, Rodriguez V, Rodriguez ML, Giro A, et al. . Selective BTK Inhibition Improves Bendamustine Therapy Response and Normalizes Immune Effector Functions in Chronic Lymphocytic Leukemia. Int J Cancer (2019) 144:2762–73.  10.1002/ijc.32010
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.32010</ArticleId>
            <ArticleId IdType="pubmed">30468254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, et al. . Phase I Study of Single-Agent CC-292, a Highly Selective Bruton’s Tyrosine Kinase Inhibitor, in Relapsed/Refractory Chronic Lymphocytic Leukemia. Haematologica (2016) 101:e295–8.  10.3324/haematol.2015.140806
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2015.140806</ArticleId>
            <ArticleId IdType="pmc">PMC5004476</ArticleId>
            <ArticleId IdType="pubmed">27151992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. . Three-Year Follow-Up of Treatment-Naive and Previously Treated Patients With CLL and SLL Receiving Single-Agent Ibrutinib. Blood (2015) 125:2497–506. 10.1182/blood-2014-10-606038
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2014-10-606038</ArticleId>
            <ArticleId IdType="pmc">PMC4400288</ArticleId>
            <ArticleId IdType="pubmed">25700432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, et al. . Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2016) 374:323–32.  10.1056/NEJMoa1509981
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1509981</ArticleId>
            <ArticleId IdType="pmc">PMC4862586</ArticleId>
            <ArticleId IdType="pubmed">26641137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kutsch N, Pallasch C, Decker T, Hebart H, Chow KU, Graeven U, et al. . A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib With and Without Obinutuzumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) [Abstract]. Blood (2019) 134(Suppl 1):3047. 10.1182/blood-2019-131025
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2019-131025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
BeiGene . Brukinsa (Zanubrutinib) [Prescribing Information]. San Mateo, CA: BeiGene USA, Inc.</Citation>
        </Reference>
        <Reference>
          <Citation>
Flinsenberg TWH, Tromedjo CC, Hu N, Liu Y, Guo Y, Thia KYT, et al. . Differential Effects of BTK Inhibitors Ibrutinib and Zanubrutinib on NK-cell Effector Function in Patients With Mantle Cell Lymphoma. Haematologica (2020) 105:e76–e9.  10.3324/haematol.2019.220590
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2019.220590</ArticleId>
            <ArticleId IdType="pmc">PMC7012496</ArticleId>
            <ArticleId IdType="pubmed">31171645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Michot JM, Ribrag V. Pirtobrutinib Shows Evidence to Inaugurate a Third Generation of BTK Inhibitors. Lancet (2021) 397:855–7.  10.1016/S0140-6736(21)00235-X
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(21)00235-X</ArticleId>
            <ArticleId IdType="pubmed">33676615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kaptein A, de Bruin G, Emmelot-van Hoek M, van de Kar B, de Jong A, Gulrajani M, et al. . Potency and Selectivity of BTK Inhibitors in Clinical Development for B-cell Malignancies [Abstract]. Blood (2018) 132(Suppl 1):1871.  10.1182/blood-2018-99-109973
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2018-99-109973</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bye AP, Unsworth AJ, Desborough MJ, Hildyard CAT, Appleby N, Bruce D, et al. . Severe Platelet Dysfunction in NHL Patients Receiving Ibrutinib is Absent in Patients Receiving Acalabrutinib. Blood Adv (2017) 1:2610–23.  10.1182/bloodadvances.2017011999
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/bloodadvances.2017011999</ArticleId>
            <ArticleId IdType="pmc">PMC5728643</ArticleId>
            <ArticleId IdType="pubmed">29296914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Series J, Garcia C, Levade M, Viaud J, Sié P, Ysebaert L, et al. . Differences and Similarities in the Effects of Ibrutinib and Acalabrutinib on Platelet Functions. Haematologica (2019) 104:2292–9.  10.3324/haematol.2018.207183
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2018.207183</ArticleId>
            <ArticleId IdType="pmc">PMC6821604</ArticleId>
            <ArticleId IdType="pubmed">30819914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, et al. . Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Phase 2 Results. Blood (2020) 135:1204–13.  10.1182/blood.2018884940
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.2018884940</ArticleId>
            <ArticleId IdType="pmc">PMC7146022</ArticleId>
            <ArticleId IdType="pubmed">31876911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Byrd JC, Woyach J, Furman RR, Martin P, SM OB, Brown JR, et al. . Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results From the Phase 1/2 ACE-CL-001 Study [Abstract]. Blood (2018) 132(Suppl 1):692. 10.1182/blood-2018-99-110451
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2018-99-110451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Byrd JC, Woyach JA, Furman RR, Martin P, O’Brien SM, Brown JR, et al. . Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia: Mature Results From Phase II Study Demonstrating Durable Remissions and Long-Term Tolerability [Abstract]. J Clin Oncol (2020) 38(15 Suppl):Abstract 8024. 10.1200/JCO.2020.38.15_suppl.8024
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2020.38.15_suppl.8024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Woyach JA, Rogers KA, Bhat SA, Blachly JS, Jianfar M, Frigault MM, et al. . Acalabrutinib With Obinutuzumab (Ob) in Treatment-Naive (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Three-year Follow-Up [Abstract]. J Clin Oncol (2019) 37(15 Suppl):Abstract 7500. 10.1200/JCO.2019.37.15_suppl.7500
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2019.37.15_suppl.7500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, et al. . Acalabrutinib Monotherapy in Patients With Chronic Lymphocytic Leukemia Who are Intolerant to Ibrutinib. Blood Adv (2019) 3:1553–62.  10.1182/bloodadvances.2018030007
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/bloodadvances.2018030007</ArticleId>
            <ArticleId IdType="pmc">PMC6517672</ArticleId>
            <ArticleId IdType="pubmed">31088809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, et al. . Phase 2 Study of Acalabrutinib in Ibrutinib (IBR)-Intolerant Patients (Pts) With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) [Abstract]. J Clin Oncol (2019) 37(15 Suppl):Abstract 7530. 10.1200/JCO.2019.37.15_suppl.7530
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2019.37.15_suppl.7530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Barr P, Smith S, Roschewski M, O’Brien S, Sharman JP, Melear J, et al. . Acalabrutinib Combined With PI3Kδ Inhibitor ACP-319 in Patients (Pts) With Relapsed/Refractory (R/R) B-cell Malignancies [Abstract]. J Clin Oncol (2018) 36(15 Suppl):Abstract 7518. 10.1200/JCO.2018.36.15_suppl.7518
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.36.15_suppl.7518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Witzig T, Maddocks KJ, de Vos S, Lyons R, Edenfield W, Sharman J, et al. . Phase 1/2 Trial of Acalabrutinib Plus Pembrolizumab (Pem) in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) [Abstract]. J Clin Oncol (2019) 37(15 Suppl):Abstract 7519. 10.1200/JCO.2019.37.15_suppl.7519
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2019.37.15_suppl.7519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Byrd JC, Owen RG, O’Brien SM, Brown JR, Hillmen P, Bitman B, et al. . Pooled Analysis of Safety Data From Clinical Trials Evaluating Acalabrutinib Monotherapy in Hematologic Malignancies [Abstract]. Blood (2017) 130(Suppl 1):4326.  10.1182/blood.V130.Suppl_1.4326.4326
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.V130.Suppl_1.4326.4326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Badillo M, Nava D, Dela Rosa M, Chen W, Wang M. Management of Adherence and Adverse Events in Patients With Mantle Cell Lymphoma Treated With Acalabrutinib: The MD Anderson Cancer Center Experience(2018). Available at: https://www.eventscribe.com//2018/posters/PPLC/SplitViewer.asp?PID=MjQ3MDE3ODAyMjQ%0D# (Accessed January 22, 2021).</Citation>
        </Reference>
        <Reference>
          <Citation>
Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinib-Associated Bleeding: Pathogenesis, Management and Risk Reduction Strategies. J Thromb Haemost (2017) 15:835–47.  10.1111/jth.13651
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jth.13651</ArticleId>
            <ArticleId IdType="pmc">PMC6152914</ArticleId>
            <ArticleId IdType="pubmed">28182323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Telford C, Kabadi SM, Abhyankar S, Song J, Signorovitch J, Zhao J, et al. . Matching-Adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma. Clin Ther (2019) 41:2357–79.e1.  10.1016/j.clinthera.2019.09.012
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinthera.2019.09.012</ArticleId>
            <ArticleId IdType="pubmed">31699438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Woyach J, Huang Y, Rogers K, Bhat SA, Grever MR, Lozanski A, et al. . Resistance to Acalabrutinib in CLL is Mediated Primarily by BTK Mutations [Abstract]. Blood (2019) 134(Suppl 1):504. 10.1182/blood-2019-127674
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2019-127674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Phillips TJ, Smith SD, Jurczak W, Robak T, Stevens DA, Farber CM, et al. . Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients With Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) [Abstract]. Blood (2018) 132(Suppl 1):4144. 10.1182/blood-2018-99-110617
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2018-99-110617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Woyach JA, Awan FT, Jianfar M, Rogers KA, Jones J, Covey T, et al. . Acalabrutinib With Obinutuzumab in Relapsed/Refractory and Treatment-Naive Patients With Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study. Blood (2017) 130(Suppl 1):432. 10.1182/blood.V130.Suppl_1.432.432
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.V130.Suppl_1.432.432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, et al. . Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results From the Phase 1/2 ACE-CL-001 Study. Blood (2017) 130(Suppl 1):498. 10.1182/blood.V130.Suppl_1.498.498
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.V130.Suppl_1.498.498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. . Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) has Significant Activity in Patients With Relapsed/Refractory B-cell Malignancies. J Clin Oncol (2013) 31:88–94.  10.1200/JCO.2012.42.7906
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2012.42.7906</ArticleId>
            <ArticleId IdType="pmc">PMC5505166</ArticleId>
            <ArticleId IdType="pubmed">23045577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. . First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia [Abstract]. Am Soc Clin Oncol Annu Meeting (Forthcoming 2021). </Citation>
        </Reference>
        <Reference>
          <Citation>
Kapoor I, Bodo J, Hill BT, Hsi ED, Almasan A. Targeting BCL-2 in B-cell Malignancies and Overcoming Therapeutic Resistance. Cell Death Dis (2020) 11:941.  10.1038/s41419-020-03144-y
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-03144-y</ArticleId>
            <ArticleId IdType="pmc">PMC7608616</ArticleId>
            <ArticleId IdType="pubmed">33139702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brown JR, Eichhorst BF, Ghia P, Kater AP, Li J, Khurana S, et al. . A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination With Venetoclax With or Without Obinutuzumab, Compared With Investigator’s Choice of Chemoimmunotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation [Abstract]. Blood (2019) 134(Suppl 1):4318.  10.1182/blood-2019-123057
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2019-123057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Davids MS, Lampson BL, Tyekucheva S, Crombie JL, Ng S, Kim AI, et al. . Updated Safety and Efficacy Results From a Phase 2 Study of Acalabrutinib, Ventoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL) [Abstract]. In: 62nd ASH Annual Meeting and Exposition. Blood (2020) 136:20–1. 10.1182/blood-2020-139864</Citation>
        </Reference>
        <Reference>
          <Citation>
Woyach JA, Blachly JS, Rogers KA, Bhat SA, Grever MR, Kittai AS, et al. . Acalabrutinib in Combination With Venetoclax and Obinutuzumab or Rituximab in Patients With Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia [Abstract]. In: 62nd ASH Annual Meeting and Exposition. Blood (2020) 136:16–8. 10.1182/blood-2020-136317</Citation>
        </Reference>
        <Reference>
          <Citation>
Li L, Zhang J, Chen J, Xu-Monette ZY, Miao Y, Xiao M, et al. . B-Cell Receptor-Mediated NFATc1 Activation Induces IL-10/STAT3/PD-L1 Signaling in Diffuse Large B-cell Lymphoma. Blood (2018) 132:1805–17.  10.1182/blood-2018-03-841015
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2018-03-841015</ArticleId>
            <ArticleId IdType="pmc">PMC6634963</ArticleId>
            <ArticleId IdType="pubmed">30209121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Khan M, Siddiqi T. Targeted Therapies in CLL: Monotherapy Versus Combination Approaches. Curr Hematol Malig Rep (2018) 13:525–33.  10.1007/s11899-018-0481-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11899-018-0481-7</ArticleId>
            <ArticleId IdType="pubmed">30535947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. . Ibrutinib Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab in First-Line Treatment of Chronic Lymphocytic Leukaemia (iLLUMINATE): A Multicentre, Randomised, Open-Label, Phase 3 Trial. Lancet Oncol (2019) 20:43–56.  10.1016/S1470-2045(18)30788-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(18)30788-5</ArticleId>
            <ArticleId IdType="pubmed">30522969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. . Murano Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood (2018) 132(Suppl 1):184.  10.1182/blood-2018-184
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2018-184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, et al. . Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia (CLL14): Follow-Up Results From a Multicentre, Open-Label, Randomised, Phase 3 Trial. Lancet Oncol (2020) 21:1188–200.  10.1016/S1470-2045(20)30443-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(20)30443-5</ArticleId>
            <ArticleId IdType="pubmed">32888452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lampson BL, Tyekucheva S, Crombie JL, Kim AI, Merryman RW, Lowney J, et al. . Preliminary Safety and Efficacy Results From a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) [Abstract]. Blood (2019) 134(Suppl 1):32. 10.1182/blood-2019-127506
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2019-127506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sheng Z, Song S, Yu M, Zhu H, Gao A, Gao W, et al. . Comparison of Acalabrutinib Plus Obinutuzumab, Ibrutinib Plus Obinutuzumab and Venetoclax Plus Obinutuzumab for Untreated CLL: A Network Meta-Analysis. Leuk Lymphoma (2020) 61:3432–9.  10.1080/10428194.2020.1811271
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10428194.2020.1811271</ArticleId>
            <ArticleId IdType="pubmed">32862749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yazdy MS, Mato AR, Roeker LE, Jarral U, Ujjani CS, Shadman M, et al. . Toxicities and Outcomes of Acalabrutinib-Treated Patients With Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients [Abstract]. Blood (2019) 134(Suppl 1):4311. 10.1182/blood-2019-130062
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2019-130062</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
